Tioma Therapeutics, Inc., a venture-stage biopharmaceutical company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers, today announced it has raised $86 million in Series A venture financing. Proceeds from this financing will be used to further develop Tioma's antibody portfolio, including its lead drug candidate -- an anti-CD47 immune checkpoint inhibitor -- through advanced proof-of-concept in human clinical trials.